# MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
Canonical URL: https://biopharmsignal.com/news/MXCT/maxcyte-reports-preliminary-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance
Ticker: MXCT
Company: MaxCyte
Source: MaxCyte
Published: 2025-11-05 13:05 EST
Original Source URL: https://investors.maxcyte.com
## Summary

MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a

## Article Body
MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025 ROCKVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a
## Recent Company News
- 2026-05-12 20:06 EST — [MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-first-quarter-2026-financial-results-and-reiterates-full-year-2026-guidance) — Source: MaxCyte
- 2026-04-29 20:05 EST — [MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026](https://biopharmsignal.com/news/MXCT/maxcyte-to-report-first-quarter-2026-financial-results-on-may-12-2026) — Source: MaxCyte
- 2026-03-31 20:05 EST — [MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MXCT/maxcyte-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: MaxCyte
- 2026-03-24 20:05 EST — [MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/MXCT/maxcyte-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-guidance) — Source: MaxCyte
- 2026-03-23 12:05 EST — [MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer](https://biopharmsignal.com/news/MXCT/maxcyte-appoints-parmeet-ahuja-as-chief-financial-officer) — Source: MaxCyte
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)